Cannabinoids as gastrointestinal anti-inflammatory drugs

Pharmacological characterization of rat VD-hemopressin(α), an α-hemoglobin-derived peptide exhibiting cannabinoid agonist-like effects in mice

(2017) Ting Zheng et al.   NEUROPEPTIDES

Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists

(2017) Shaness A. Grenald et al.   NEUROPHARMACOLOGY

Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies

(2016) Marco Migliore et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Abnormal cannabidiol attenuates experimental colitis in mice, promotes wound healing and inhibits neutrophil recruitment

(2016) Regina M. Krohn et al.   Journal of Inflammation-London

May cannabinoids prevent the development of chemotherapy-induced diarrhea and intestinal mucositis? Experimental study in the rat

(2016) R. Abalo et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase

(2016) Anne Kerbrat et al.   NEW ENGLAND JOURNAL OF MEDICINE

An Orally Active Cannabis Extract with High Content in Cannabidiol attenuates Chemically-induced Intestinal Inflammation and Hypermotility in the Mouse

(2016) Ester Pagano et al.   Frontiers in Pharmacology

Multitarget fatty acid amide hydrolase/cyclooxygenase blockade suppresses intestinal inflammation and protects against nonsteroidal anti-inflammatory drug-dependent gastrointestinal damage

(2015) Oscar Sasso et al.   FASEB JOURNAL

Role of G Protein-coupled Orphan Receptors in Intestinal Inflammation

(2015) Andrzej Wasilewski et al.   INFLAMMATORY BOWEL DISEASES

Role of Transient Receptor Potential Channels in Intestinal Inflammation and Visceral Pain

(2015) Marta Zielińska et al.   INFLAMMATORY BOWEL DISEASES

The GPR55 antagonist CID16020046 protects against intestinal inflammation

(2015) A. Stančić et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Novel orally available salvinorin A analog PR-38 protects against experimental colitis and reduces abdominal pain in mice by interaction with opioid and cannabinoid receptors

(2014) Maciej Sałaga et al.   BIOCHEMICAL PHARMACOLOGY

Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent

(2014) Francesca Borrelli et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cannabis Use Provides Symptom Relief in Patients with Inflammatory Bowel Disease but Is Associated with Worse Disease Prognosis in Patients with Crohnʼs Disease

(2014) Martin Storr et al.   INFLAMMATORY BOWEL DISEASES

Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid metabolites induced by selective inhibition of fatty acid amide hydrolase (FAAH)

(2014) M. Sałaga et al.   Journal of Crohns & Colitis

Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease

(2013) Francesca Borrelli et al.   BIOCHEMICAL PHARMACOLOGY

Cannabis Induces a Clinical Response in Patients With Crohn's Disease: A Prospective Placebo-Controlled Study

(2013) Timna Naftali et al.   Clinical Gastroenterology and Hepatology

Inhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tract

(2013) Maciej Sałaga et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty acid amides

(2013) J. Fichna et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Transient Receptor Potential Vanilloid 4 blockade protects against experimental colitis in mice: a new strategy for inflammatory bowel diseases treatment?

(2012) J. Fichna et al.   NEUROGASTROENTEROLOGY AND MOTILITY

An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee

(2012) John P. Huggins et al.   PAIN

The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity

(2012) Mireille Alhouayek et al.   TRENDS IN MOLECULAR MEDICINE

Cannabinoids and the gut: New developments and emerging concepts

(2010) Angelo A. Izzo et al.   PHARMACOLOGY & THERAPEUTICS

Functional CB2 type cannabinoid receptors at CNS synapses

(2009) Nicola H. Morgan et al.   NEUROPHARMACOLOGY

Cannabinoid CB2receptors in the gastrointestinal tract: a regulatory system in states of inflammation

(2007) K L Wright et al.   BRITISH JOURNAL OF PHARMACOLOGY